Skip to content
Episurf Medical AB’s 2022 annual report is now available

Episurf Medical’s annual report for 2022 is available as of today at the company’s website, www.episurf.com

Episurf Medical has of environmental and cost reasons chosen not to print the annual report. A printed version of the annual report will be distributed to shareholders and others who made such request. The annual report can also be ordered from Episurf Medical on the following address: Episurf Medical AB, Karlavägen 60, 114 49 Stockholm, Sweden or by email: ir@episurf.com.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 17.30 CEST on 4 April 2023.

CisionBlockPro\Cision\FeedItem Object
(
    [HtmlCompanyInformation:protected] => <p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><strong><span style="font-size:10pt">About Episurf Medical</span></strong></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><span style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>This information is information that Episurf Medical AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 17.30 CEST on 4 April 2023.</em></span></p>
    [HtmlContact:protected] => <p><strong><span><span style="font-size:10pt"><span style="font-family:arial,helvetica,sans-serif">For more information, please contact:</span></span></span></strong></p>
<p><span><span style="font-size:10pt"><span style="font-family:arial,helvetica,sans-serif"><span style="font-size:10pt"><span><span style="font-family:arial,helvetica,sans-serif">Pål Ryfors, CEO, Episurf Medical</span></span></span><br>
Tel:<span style="font-size:10pt">+46 (0) 709 62 36 69</span><br>
<span style="font-size:10pt">Email:&nbsp;</span><a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></span></span></span></p>
<p><span><span><span style="font-size:10pt"><span style="font-family:arial,helvetica,sans-serif">Veronica Wallin, CFO, Episurf Medical</span></span></span></span><br>
<span><span><span style="font-size:10pt"><span style="font-family:arial,helvetica,sans-serif">Tel:</span></span></span></span><span><span><span style="font-size:10pt"><span style="font-family:arial,helvetica,sans-serif">+46 (0) 700 37 48 95</span></span></span></span><br>
<span style="font-size:10pt"><span><span style="font-family:arial,helvetica,sans-serif">Email:&nbsp;</span></span></span><a href="mailto:pal.ryfors@episurf.com"><span><span style="font-size:10pt"><span style="font-family:arial,helvetica,sans-serif">veronica.wallin@episurf.com</span></span></span></a></p>
    [HtmlTitle:protected] => <h1 style="line-height:120%">Episurf Medical AB&rsquo;s 2022 annual report is now available</h1>
    [HtmlHeader:protected] => 
    [HtmlIntro:protected] => 
    [Body:protected] => Episurf Medical’s annual report for 2022 is available as of today at the company’s website, www.episurf.com. 
Episurf Medical has of environmental and cost reasons chosen not to print the annual report. A printed version of the annual report will be distributed to shareholders and others who made such request. The annual report can also be ordered from Episurf Medical on the following address: Episurf Medical AB, Karlavägen 60, 114 49 Stockholm, Sweden or by email: ir@episurf.com.
    [HtmlBody:protected] => <p style="margin-top:12px"><span>Episurf Medical&rsquo;s annual report for 2022 is available as of today at the company&rsquo;s website,&nbsp;<a href="https://www.episurf.com/">www.episurf.com</a>.&nbsp;</span></p>
<p><span>Episurf Medical has of environmental and cost reasons chosen not to print the annual report. A printed version of the annual report will be distributed to shareholders and others who made such request. The annual report can also be ordered from Episurf Medical on the following address: Episurf Medical AB,&nbsp;Karlav&auml;gen 60,&nbsp;114 49 Stockholm,&nbsp;Sweden or by email:&nbsp;<a href="mailto:ir@episurf.com">ir@episurf.com</a>.</span></p>
    [ServiceCategories:protected] => Array
        (
            [0] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => EU Transparency SE
                    [Name:protected] => SeFsaCategoryCode
                    [Value:protected] => R1
                )
            [1] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => OMX Filing (OMX CNS)
                    [Name:protected] => OMX CategoryCode
                    [Value:protected] => 270
                )
            [2] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => Twitter
                    [Name:protected] => Twitter
                    [Value:protected] => 9341
                )
            [3] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => LinkedIn
                    [Name:protected] => LinkedIn
                    [Value:protected] => 14747
                )
            [4] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => Facebook
                    [Name:protected] => Facebook
                    [Value:protected] => 15237
                )
        )
    [LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
    [CompanyInformation:protected] => About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 17.30 CEST on 4 April 2023.
    [Contact:protected] => For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com (pal.ryfors@episurf.com)
    [Header:protected] => 
    [Keywords:protected] => Array
        (
        )
    [QuickFacts:protected] => Array
        (
        )
    [Categories:protected] => Array
        (
        )
    [Videos:protected] => Array
        (
        )
    [Files:protected] => Array
        (
            [0] => CisionBlockPro\Cision\File Object
                (
                    [IsMain:protected] => 1
                    [MediaType:protected] => File
                    [Url:protected] => https://mb.cision.com/Main/14691/3747160/1968988.pdf
                    [FileName:protected] => wkr0006.pdf
                    [Title:protected] => Annual Report 2022 ENG
                    [Description:protected] => Annual Report 2022 ENG
                    [CreateDate:protected] => 2023-04-04T15:30:17.233Z
                    [Keywords:protected] => Array
                        (
                        )
                    [Extension:protected] => pdf
                )
            [1] => CisionBlockPro\Cision\File Object
                (
                    [IsMain:protected] => 
                    [MediaType:protected] => Esef
                    [Url:protected] => https://mb.cision.com/Main/14691/3747160/1968989.zip
                    [FileName:protected] => wkr0008.zip
                    [Title:protected] => 549300GORBCSMHZB2J75-2022-12-31-sv (2).zip
                    [Description:protected] => 549300GORBCSMHZB2J75-2022-12-31-sv (2).zip
                    [CreateDate:protected] => 2023-04-04T15:30:17.25Z
                    [Keywords:protected] => Array
                        (
                        )
                    [Extension:protected] => zip
                )
        )
    [Quotes:protected] => Array
        (
        )
    [ExternalLinks:protected] => Array
        (
        )
    [EmbeddedItems:protected] => Array
        (
        )
    [Id:protected] => 4509519
    [EncryptedId:protected] => 0886C4799314657A
    [IsRegulatory:protected] => 1
    [PublishDate:protected] => 2023-04-04T15:30:00Z
    [LastChangeDate:protected] => 2023-04-04T15:30:17.233Z
    [Title:protected] => Episurf Medical AB’s 2022 annual report is now available
    [Intro:protected] => 
    [IptcCode:protected] => 04016003
    [InformationType:protected] => RDV
    [LanguageCode:protected] => en
    [CountryCode:protected] => se
    [CanonicalUrl:protected] => 
    [CisionWireUrl:protected] => https://news.cision.com/episurf/r/episurf-medical-ab-s-2022-annual-report-is-now-available,c3747160
    [LanguageVersions:protected] => Array
        (
        )
    [Images:protected] => Array
        (
        )
    [Tickers:protected] => Array
        (
            [0] => stdClass Object
                (
                    [Symbol] => EPIS B
                    [ISIN] => SE0003491562
                    [PrimaryListing] => 1
                    [IsShare] => 1
                    [MarketPlaceSymbol] => STO
                    [MarketPlaceName] => Stockholmsbörsen
                    [MarketPlaceBloombergCode] => SS
                    [MarketPlaceMarketWireCode] => OMX
                    [MarketPlaceIsRegulated] => 1
                    [MarketPlaceCountryCode] => SE
                )
        )
)